Now showing items 1-7 of 7

    • Combination inhibition of PI3K and mTORC1 yields durable remissions in orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases 

      Ni, Jing; Ramkissoon, Shakti H.; Xie, Shaozhen; Goel, Shom; Stover, Daniel G.; Guo, Hanbing; Luu, Victor; Marco, Eugenio; Ramkissoon, Lori A.; Kang, Yun Jee; Hayashi, Marika; Nguyen, Quang-De; Ligon, Azra H.; Du, Rose; Claus, Elizabeth B.; Alexander, Brian M.; Yuan, Guo-Cheng; Wang, Zhigang C.; Iglehart, J. Dirk; Krop, Ian E.; Roberts, Thomas M.; Winer, Eric P.; Lin, Nancy U.; Ligon, Keith L.; Zhao, Jean J. (2016)
      Brain metastases represent the greatest clinical challenge in treating HER2-positive breast cancer. We report the development of orthotopic patient-derived xenografts (PDXs) of HER2-expressing breast cancer brain metastases ...
    • Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs 

      Marquard, Andrea M; Eklund, Aron C; Joshi, Tejal; Krzystanek, Marcin; Favero, Francesco; Wang, Zhigang C; Richardson, Andrea L; Silver, Daniel P; Szallasi, Zoltan; Birkbak, Nicolai J (BioMed Central, 2015)
      Background: Ovarian and triple-negative breast cancers with BRCA1 or BRCA2 loss are highly sensitive to treatment with PARP inhibitors and platinum-based cytotoxic agents and show an accumulation of genomic scars in the ...
    • Prevalence and Predictors of Loss of Wild Type BRCA1 in Estrogen Receptor Positive and Negative BRCA1-Associated Breast Cancers 

      Fetten, Katharina; Yassin, Yosuf; Buraimoh, Ayodele; Kim, Ji-Young; Legare, Robert D; Tung, Nadine Muskatel; Miron, Alexander; Schnitt, Stuart Jay; Gautam, Shiva Prasad; Kaplan, Jennifer; Szasz, Attila M.; Tian, Ruiyang; Wang, Zhigang C.; Collins, Laura Christine; Brock, Jane Elizabeth; Krag, Karen; Sgroi, Dennis Charles; Ryan, Paula D.; Silver, Daniel P.; Garber, Judy Ellen; Richardson, Andrea Lynn (BioMed Central, 2010)
      Introduction: The majority of breast cancers that occur in BRCA1 mutation carriers (BRCA1 carriers) are estrogen receptor-negative (ER-). Therefore, it has been suggested that ER negativity is intrinsic to BRCA1 cancers ...
    • PRKACA Mediates Resistance to HER2-Targeted Therapy in Breast Cancer Cells and Restores Anti-Apoptotic Signaling 

      Moody, Susan E.; Schinzel, Anna C.; Singh, Shambhavi; Izzo, Francesca; Strickland, Matthew R.; Luo, Leo; Thomas, Sapana R.; Boehm, Jesse S.; Kim, So Young; Wang, Zhigang C.; Hahn, William C. (2014)
      Targeting HER2 with antibodies or small molecule inhibitors in HER2-positive breast cancer leads to improved survival, but resistance is a common clinical problem. To uncover novel mechanisms of resistance to anti-HER2 ...
    • PTK6 Regulates IGF-1-Induced Anchorage-Independent Survival 

      Iida, Naoko; Zou, Lihua; Yao, Jun; Lu, Yiling; Epstein, Charles B.; Natesan, Sridaran; Mills, Gordon B.; Irie, Hanna Yoko; Shrestha, Yashaswi; Selfors, Laura Marie; Frye, Fabianne; Wang, Zhigang C.; Richardson, Andrea Lynn; Polyak, Kornelia; Hahn, William C.; Brugge, Joan S. (Public Library of Science, 2010)
      Background: Proteins that are required for anchorage-independent survival of tumor cells represent attractive targets for therapeutic intervention since this property is believed to be critical for survival of tumor cells ...
    • RelA-Induced Interferon Response Negatively Regulates Proliferation 

      Kochupurakkal, Bose S; Wang, Zhigang C.; Hua, Tony; Culhane, Aedin; Rodig, Scott J.; Rajkovic-Molek, Koraljka; Lazaro, Jean-Bernard; Richardson, Andrea; Biswas, Debajit Kumar; Iglehart, James Dirk (Public Library of Science (PLoS), 2015)
      Both oncogenic and tumor-suppressor activities are attributed to the Nuclear Factor kappa B (NF-kB) pathway. Moreover, NF-kB may positively or negatively regulate proliferation. The molecular determinants of these opposing ...
    • Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations 

      Birkbak, Nicolai Juul; Kochupurakkal, Bose; Izarzugaza, Jose M. G.; Eklund, Aron C.; Li, Yang; Liu, Joyce; Szallasi, Zoltan; Matulonis, Ursula A.; Richardson, Andrea L.; Iglehart, J. Dirk; Wang, Zhigang C. (Public Library of Science, 2013)
      Background: Increased number of single nucleotide substitutions is seen in breast and ovarian cancer genomes carrying disease-associated mutations in BRCA1 or BRCA2. The significance of these genome-wide mutations is ...